T wo general models for tumor initiation and heterogeneity have been proposed (1, 2) . In the stochastic model, most, if not all, tumor cells can reinitiate and propagate the tumor. By contrast, the cancer stem cell (CSC) model holds that only some cells indefinitely self-renew and sustain tumor growth. In the stochastic model, therapy resistance results from genetic/epigenetic alterations that diminish the sensitivity of tumor cells to antineoplastic agents. In the CSC model, treatment failure can reflect the relative inability of agents to target CSCs, which may be intrinsically more resistant (3, 4) . Distinguishing between these models has obvious implications for cancer biology and therapy.
Human tumor-initiating cells (TICs) can be defined operationally as cells capable of initiating a tumor in immunodeficient mice. In the CSC model, TICs are generally thought to be rare, although this is not obligatory (5) . Moreover, the stochastic model does not mandate that TICs are numerous: tumor cells might oscillate between a more frequent nontumorigenic and a less common tumorigenic state, as has been proposed for tumor cells undergoing epithelial-mesenchymal transition (6) . The essential feature of the CSC model is that tumors are hierarchically organized such that TICs and non-TICs are distinguishable by phenotype; i.e., it should be possible to prospectively purify a stable population with the unique ability to generate serially transplantable tumors that recreate the heterogeneity of the patient malignancy. By contrast, the stochastic model predicts that TICs distribute into all cell fractions.
The first, and still the most compelling, evidence for CSCs arose from studies of acute myelogenous leukemia, wherein only CD34 + (and later, CD34 + CD38 − ) cells gave rise to leukemic grafts following xenotransplantation (7, 8) . Later, analogous studies argued for CSCs in epithelial (9-13) and neuroectodermal (14) (15) (16) tumors. However, several criticisms of the CSC model have emerged. Hill notes that putative CSC fractions are quite impure, with substantial numbers of TICs found in markerpositive and -negative populations (17) . Similarly, Kern and Shibata criticize the lack of quantitative rigor in most reports and argue that the absolute number and relative enrichment of putative CSCs have been markedly overestimated (18) . Morrison et al. reported that xenograft assays underestimate TIC frequency (TICf) in at least some malignancies. For example, when assayed in NOD/SCID mice, melanoma TICs seem rare and can be enriched on the basis of ABCB5 expression (16) . However, when NOD/SCID/IL2Rγ −/− (NSG) mice are the recipients, up to onefourth of melanoma cells are capable of tumor initiation, and 0/21 markers tested enrich for TICs (19, 20) .
These criticisms have merit, yet they do not disprove the CSC model (5) . Rather, they emphasize the need for more precise markers and optimized, quantitative assays. However, limited tumor material makes TIC quantification challenging. Indeed, many previous studies estimated TICf by pooling data from different patients (9, 10, 12) , assuming a similar TICf in independent tumors. Others used fractionated cells from passaged xenografts, without evidence that xenograft-and primary tumorderived TICs have the same phenotype.
High grade serous ovarian cancer (SOC) is the leading cause of morbidity and mortality from gynecologic malignancy (21, 22) . SOC typically presents with abdominal masses and ascites, providing ample experimental material. Optimal surgical debulking and platinum/taxane-based chemotherapy significantly prolong survival. However, 70-90% of SOC patients relapse and die of their disease (23) , raising the possibility that intrinsically resistant CSCs account for tumor initiation, treatment failure and relapse.
Previous studies have claimed that CD44 with or without CD117 (24, 25) , side population (26), CD24, epithelial cell adhesion molecule (EpCAM) (27) , and/or CD133 (28) expression enrich for SOC TICs. These studies used cultured primary cells (24, 25, 29, 30) , multiply passaged primary xenografts (28), or immortalized cell lines (26, 27) and did not report the total number of TICs in each fraction. To test whether primary SOC conforms to the CSC model, we developed a robust, quantitative assay for SOC TICs and quantified and characterized TICs from multiple primary SOC samples and xenografts.
Results
Development of a Xenotransplant Assay for Primary SOC. We obtained samples from 138 typical SOC patients (Table S1 ). On average, ∼30% of solid tumor and ∼40% of ascites cells were CD45 + leukocytes and could be removed using anti-CD45 paramagnetic microbeads (Fig. S1) . Injection of 10 6 CD45-depleted SOC cells into the peritoneal cavity, kidney capsule, ovarian bursa or mammary fat pad of NOD/SCID mice resulted in high tumor takes (Fig. 1A) . Small tumors (1-2 mm) could be detected most rapidly and reliably in the mammary fat pad (Fig. 1B) ; TICf, quantified by limiting dilution assay (LDA), was also highest at this site (Fig. 1C) . Mammary fat pad xenografts recapitulated the inter-and intratumor heterogeneity of primary SOC, as assessed by histology (Fig. 1D ), surface immunophenotype (Fig. 1E) , and expression of p53, WT1, and CK7 (Fig. S2 ). For these reasons (and others; Discussion), we used the mammary fat pad for all subsequent experiments.
Tumor-Initiating Cells in SOC Are Rare. As large numbers of cells were available from most samples, we could use LDA to estimate the TICf from multiple SOC cases ( Fig. 2A) (31) . Although the median TICf was ∼1/40,000 (Fig. 2B) , in individual tumors, TICf varied widely (1/1,400-1/911,000). TICf was similar in unpaired SOC cases presenting as ovarian masses (n = 16) or omental metastases (n = 11, Fig. 2B ), as well as in five paired samples (Fig.  2C) . Thus, TICf appears to be a stable and distinct characteristic of each solid tumor. The median TICf from malignant ascites was 1/10,000 (range 1/700-1/118,000, Fig. 2D ), significantly higher than that measured in solid tumor samples (P = 0.0004, unpaired). There was no significant difference in TICf in ascites samples from patients with primary (chemotherapy naive, n = 3; neo-adjuvant chemotherapy treated, n = 2) and recurrent (n = 20) disease (Kruskal-Wallis test), nor did TICf (n = 41) correlate in uni-or multivariate analyses with age, stage, debulking status, progression-free survival (including change in CA125), or overall survival. Although TICf was higher in NSG (compared with NOD/SCID) mice in 4/10 cases, in every case only a small fraction (≤0.02%) of SOC cells could initiate tumors (Fig. 2E) ; thus, we conclude that TICs in SOC are rare.
All xenografts could be passaged from one to three times (Fig. 1A) , indicating the presence of self-renewing tumor cells. TICf remained constant upon serial passage of some, but not all, xenografts (Fig. 2 F and G) . This difference was not associated with the patient's clinical history (including prior chemotherapy treatment or disease recurrence). Although xenografts remained clearly identifiable as SOC, some regional changes in nuclear and morphological histology emerged by the third passage (Fig. 1D ).
CD133 Enriches for TICs, but the TIC Phenotype Is Heterogeneous and Unstable. Low TICf and the ability to passage tumors are consistent with, but do not prove, the CSC model, which also requires prospective purification of TICs. CD133 is a transmembrane glycoprotein typically localized to apical plasma membrane protrusions in epithelial cells (32) and potentially involved in cell polarization (33) . A purported CSC marker in several tumor types (11, 12, (34) (35) (36) , CD133 expression is also associated with some normal stem cells (36, 37) . While this work was in progress, it was reported that CD133 enriches for TICs from multiply passaged SOC xenografts (28) . Flow cytometric analysis of 108 primary SOCs revealed CD133 expression in all cases, typically on only a small percentage of cells (median = 3%, range = 0.1-92%, Fig.  3A ). Therefore, we quantified the tumorigenicity of CD133 + and CD133
− fractions from multiple SOC cases (Table 1) ; in these studies, each fraction was 98-100% pure (Fig. 3B) . If sufficient cells were available, we also quantified TICf in unfractionated cells. First, we assayed five primary solid tumors, two with matched omental metastases (patients 1 and 2). For both paired cases, all TICs were CD133 + , representing a 20-to 100-fold purification. As for unfractionated cells (Fig. 2C ), the frequency of CD133 + TICs was similar in the primary tumor and its matched metastasis. In the other three cases, CD133
+ cells had enhanced tumorigenicity, and although there were TICs in the CD133 − fraction, the majority of total TICs were CD133 + . In 4/10 ascites samples, the CD133 + fraction was enriched substantially for TICs compared with the CD133 − fraction. In another 4/10, both populations were highly tumorigenic, with the CD133 − fraction occasionally yielding tumors even at the lowest dose (10,000 cells for 14A). Total TICs in these cases were equal or greater in the CD133
− fraction compared with the CD133 + compartment. However, in the remaining two ascites samples the CD133 − fraction contained all or most tumorigenic cells (15A, 16A).
Conceivably, in cases with predominantly CD133 + TICs, tumors from "CD133 − " cells resulted from contamination with CD133 + cells. Using the measured purity and TIC frequencies of each fraction, we calculated the probability that tumors from CD133 − cells arose from contaminating CD133 + cells (Table  S2 ). For two solid tumors and one ascites case, we could not exclude (at the 99% confidence level) this possibility. However, in one solid tumor and four ascites samples, TICs in the CD133 − fraction were clearly not due to contamination, implying bona fide heterogeneity of the TIC phenotype. This heterogeneity was exemplified most strikingly by the two ascites cases in which all TICs were CD133 − . It is unlikely that CD133 − TICs reflect loss of the glycosylation-sensitive epitope recognized by monoclonal antibody AC133, as there was near-absolute correlation between staining with AC133 and monoclonal antibody 293C3 (Fig. S3 ), which recognizes a distinct epitope (38) . Taken together, our data indicate that TICs can be prospectively purified from primary SOC, but the TIC phenotype is heterogeneous: TICs from some SOCs are marked by CD133 expression; in other cases, lack of CD133 expression marks TIC; and still in others, CD133 has no (or little) apparent relevance to the TIC phenotype.
In contrast to primary SOC samples, in only one of nine xenografts (10Ap1) were all TICs CD133 + . CD133 expression enriched for TICs in three other cases; in one (17Tp1) a clear majority and in another (18Tp1) a slight excess of total TICs were CD133 + . However, these three xenografts all contained signifi- 
cant numbers of CD133
− TICs, and in case 7Ap1, there were 10 times more TICs in the CD133 − fraction. In two of these three cases, tumors arising from CD133 − cells were not explicable by contamination. Three other xenografts showed comparable TIC activity in the CD133 + and CD133 − fractions (19Ap1, 20Tp1) or were not evaluable (21Mp1) because all mice had tumors even at the lowest dose of CD133 − cells tested. In all of these cases, the total number of TICs was higher in the CD133
− compared with the CD133 + fraction, and tumors arising from CD133 − cells could not be explained by contamination (Table S2 ). In the remaining two xenografts, all TICs were CD133 − . To gain further insight into the basis of the heterogeneity in TIC phenotype, we quantified the tumorigenicity of CD133 + and CD133 − cells from two matched primary tumors and xenografts. In the first case (7A), TICs from the patient sample were exclusively CD133
+ , but in the xenograft, most TICs were CD133 − . Similarly, most TICs from the second patient sample (9A) were CD133 + (and the apparent CD133 − TICs could have reflected contamination), but all TICs from the xenograft resided in the CD133 − fraction. Consistent with the predictions of the CSC model, xenografts arising from CD133 + TICs gave rise to both CD133 + and CD133 − populations, regenerated the histology of the primary tumor ( Fig. 3 C and D) , and could be serially transplanted. However, tumors that arose from CD133 − TICs also had these properties.
Other Candidate Markers Are Less/Non-Discriminatory for SOC TICs.
Finally, we evaluated CD44, CD117, EpCAM and aldehyde dehydrogenase 1 (ALDH1) as potential markers for SOC TICs. In contrast to a report that SOC CSCs were CD117 + /CD44 + (24), only 30% of primary SOC (n = 81) and first passage xenografts (n = 31) had cells coexpressing these markers (Fig. S4 A and B) + fractions from two first passage xenografts (Fig. S5B ), indicating that CD44 does not uniquely identify TICs in these cases. EpCAM expression was heterogeneous in SOC (n = 20), but EpCAM + and EpCAM − fractions both contained significant numbers of tumorigenic cells in two of three samples tested (Fig.  S6) . ALDH1 activity, a reported functional marker of some putative CSC (39-41) and normal stem cells (42) (43) (44) , was present in most SOC tumors (92%, n = 12) and ascites (95%, n = 20, Fig. S7  A and B) . High ALDH1 activity enriched for TICs in five of six cases, but to a lesser extent than CD133 (P = 0.007, MannWhitney test, Fig. S7C ). In most (four of six) cases, total TICs were comparable in the ALDH1 hi and ALDH1 lo populations, and in one case (23A), all TICs were ALDH lo . Furthermore, tumors arising from the ALDH lo population could not be explained by contaminating ALDH1
hi cells (Fig. S7C ).
Discussion
Several groups have claimed to identify ovarian CSCs, but their reports relied on arguably nonfidelitous models (24) (25) (26) (27) (28) (29) . We established a robust, quantitative assay that enables characterization of TICs from primary SOC. Using this assay, we find that SOC TICs are rare, even when measured in NSG mice. Consistent with the CSC model, TICs can be prospectively enriched from primary SOC. However, the TIC phenotype is not uniform across patients, nor is it stable in xenografts. Our data have important implications and caveats for future studies of the biology of TICs in SOC and possibly other malignancies. Recent work shows that injection conditions and the degree of immunodeficiency of the xenograft recipient can affect TICf dramatically (19) . Moreover, in some syngeneic models, most tumor cells are capable of reinitiating tumors (5, (45) (46) (47) . These results raised the possibility that studies using NOD/SCID xenografts underestimated TIC frequencies and that TICs are common in many tumors.
We also find that experimental variables influence TICf. For example, tumor take and TICf are substantially higher in the mammary fat pad than in other sites. We cannot exclude the unlikely possibility that TICs measured in the mammary fat pad might differ from those measured elsewhere. However, mammary fat pad xenografts recapitulate the histology and immunophenotype of the original tumor. Moreover, a suboptimal microenvironment would presumably result in a lower, not higher, TICf. In fact, the mammary fat pad might provide a microenvironment more similar to that of human SOC than "more relevant" sites (e.g., peritoneal cavity). In humans, SOC grows on the omentum (48), which is adipose rich (49) . By contrast, the murine omentum contains little fat (49) . The markedly higher TICf in the mammary fat pad raises the possibility that the adipose-rich environment of the human omentum might aid SOC growth. In some cases, TICf was ∼10-fold higher in NSG vs. NOD/ SCID mice, yet even then TICs represented ≤0.02% of CD45-depleted SOC cells. Due to a lack of reliable markers, we could not remove potentially contaminating stromal cells (aside from leukocytes). We also found that in contrast to a recent publication examining ovarian cancer cell lines (27) , the epithelial marker EpCAM does not mark all tumorigenic primary SOC cells and thus cannot be used for positive selection. Even with stromal contamination as high as 90%, however, TICf would be underestimated by at most 10-fold. We acknowledge that in this study, as in others that use xenografts, one cannot exclude the possibility that the xenogenic microenvironment results in an underestimation of the TICf of human cancer cells. Within these acknowledged limitations, and using our most sensitive assay, we conclude that TICs in SOC are rare. Notably, TICs also are rare in several other tumor types, independent of the extent of immunodeficiency of the xenograft recipients (50) .
Our studies reveal several properties of TICs in SOC. First, TICf varies up to 100-fold between patients, indicating the need to assess TICf on a patient-by-patient basis and calling into question published studies based on pooled samples (9, 10, 12) . Second, TICf is similar in primary tumors and matched omental metastases. Recent work suggests that SOC might arise from the fallopian tube epithelium (51) (52) (53) , in which case ovarian masses actually would be metastases. Alternatively, if SOC originates from the ovarian surface epithelium, then our data indicate that TICs are maintained at similar proportions in primary tumors and metastases. Either way, TICf is an intrinsic property of each patient's tumor and SOC metastases contain TICs. Third, TICf is substantially higher in ascites than in solid tumors. Conceivably, TICs might be able to survive better or differentiate less in ascitic fluid. Alternatively, it might simply be easier to dissociate ascites samples while maintaining TIC viability. Finally, whereas TICf is stable upon serial passage in some cases, it increases in others, suggesting that TICs from some patients evolve more rapidly in the xenogenic environment. This difference might reflect variable degrees of genomic instability; indeed, many SOCs lack functional p53 and BRCA1/2 (54-56).
The CSC model requires that TICs be amenable to prospective purification. It was reported previously that cultured primary SOC cells that coexpress CD117 and CD44 are enriched for TICs (24) . However, we found that most SOCs do not have CD117 + cells, even fewer have a CD117 + /CD44 + population, and, when present, neither population is enriched for TICs. These differences may reflect the use of cultured SOC cells and less immunodeficient (SCID) recipients in the prior work. We also find that CD44, alone or in combination with CD133, does not mark TICs in primary SOC, contrary to reports that used cultured SOC cells (25, 27) .
By contrast, CD133 is always expressed on a subpopulation of primary SOC cells and can be used to prospectively enrich for TICs in many cases. Remarkably though, this marker also reveals heterogeneity of the TIC phenotype. ) types of CSC in this disease. Previous studies using CD133 as a marker also suggested, although did not prove, that the TIC phenotype is heterogeneous. Specifically, these studies demonstrated that CD133 does not mark all TICs in every case of glioblastoma (57-59) and colon cancer (12, 60) .
Interestingly, the TIC phenotype deteriorates in xenografts: Most primary SOC TICs are CD133 + , but in only one case do xenograft TICs have this phenotype. While our work was in progress, it was reported that CD133 enriched for TICs from a small number of multiply passaged, pooled SOC xenografts (28) . In that study, tumors also arose from the CD133 − fraction, which the authors attributed to contamination with CD133 + cells. We reanalyzed their data and note that contamination cannot account for CD133
− xenografts (Table S3 ). The most parsimonious explanation for these findings is that CD133 − cells, due to additional genetic/epigenetic changes, can (re)acquire selfrenewal ability and become TICs. Consistent with this notion, CD133 marks TICs in most (four of five) solid tumors (when potential contamination is taken into consideration), whereas CD133 − TICs are mainly observed in ascites and/or xenografts (which probably reflect more advanced disease). Furthermore, in two paired primary cases, we recovered CD133 − TICs from xenografts arising from primary tumors with exclusively CD133 TICs. Similar events could explain the coexistence of CD133 + and CD133 − TICs in other SOCs. Moreover, an analogous switch in CSC phenotype is believed to occur during conversion from the chronic phase of chronic myeloid leukemia, in which CSCs reside within the hematopoietic stem cell compartment, to myeloid blast crisis where CSCs arise from granulocyte/macrophage progenitors (61) . It will be interesting to see if specific genetic alterations correlate with the different TIC phenotypes; indeed, preliminary copy number variation analyses reveal dramatic differences in xenografts derived from some CD133
− TICs compared with parental CD133 + TICs. Alternatively, given that CD133 clearly is not an obligate, functional marker of SOC TICs, we cannot exclude the possibility that the CD133 − TICs that arise in xenografts simply reflect the influence of the altered microenvironment on CD133 expression.
Regardless, the increased number and frequency of CD133 − TICs, in combination with the observed histological changes in early passage xenografts, argue for extreme caution when using these models to infer the phenotype of patient TICs. Furthermore, the phenotypic heterogeneity and instability of TICs could complicate efforts to translate CSC concepts to the clinic. Nevertheless, our identification of different phenotypic classes of TICs in primary patient samples provides a platform for the identification of additional selective markers and the detailed molecular characterization of this potentially important population of SOC cells.
Materials and Methods
High-grade SOC samples were obtained from the University Health Network Tissue Bank with patient consent. Samples were mechanically/enzymatically digested to generate single-cell suspensions and red blood cells/leukocytes were depleted. Flow cytometry and FACS were conducted as described in SI Materials and Methods, using gating strategies shown in Fig. S8 . CD45-depletedcells (10 6 ) in 1:1 HBSS:Matrigel (BD Biosciences) were injected into the mammary fat pad, renal capsule, ovarian bursa, or peritoneum of NOD/SCID or NSG mice. The mammary fat pad was found to be superior and was used for subsequent experiments. For LDA, three cell doses of bulk or fractionated cells were injected. Mice were monitored for tumors for up to 6 mo or until moribund and tumors were harvested for studies or passaging. Additional methods and description of statistical analyses are in SI Materials and Methods. 
XenograŌs
Primary and xenograft-derived SOC cells were fractionated for CD133 expression and were injected into NOD/SCID mice (four mice per dose, two or more doses per fraction). TICf was calculated as described in Fig. 2A + and CD133 − SOC cells, the recovery of TIC activity (i.e., total TICs from unfractionated cells compared with the sum of CD133 + and CD133 − TICs) ranged from 5% to 800%. Low recovery could reflect losses during sorting, gating strategy or, potentially, a supportive effect of non-TICs on TICs; high recovery could indicate inhibitory effects of non-TICs on TICs. In addition, the practical limitations on the number and range of tumor cell doses that can be tested and the number of recipient mice per dose intrinsically limit the accuracy of LDAs.
